Relative air humidity is 70% and cloudiness 6.1 tenths. Zenica's population increased from 7,215 citizens in 1910 to 15,550 in 1948 and 63,869 in 1981.Many Serbs after the Bosnian War fled from the Zenica (either voluntarily or not);The most common surname in Zenica is Delić (983 persons).In Zenica-Doboj Canton, as of February 2020, most common surnames are (descending incidence, all with incidence >1,000 are listed):In the pre-war period (in 1990), Zenica produced, among others, 1.4 tons of steel and 924,000 tons of coal, 1,018,000 mThe most notable metal-sector companies from Zenica are ArcelorMittal, Femetall, Cimos, RM-LH, Bosio, Treasure.
When the largest steel producer in the world, ArcelorMittal, considered expanding to Bosnia and Herzegovina they turned to the EBRD.
The EBRD was a pioneer in the development of private pension management in
As one moves towards east and west, altitudes increase; thus, northwestern and northeastern areas of the city are the highest.Zenica city is characterized by many small rivers and streams; all of them completely belong to the Bosna river basin. - Active character: Character has logged in within 30 days. Name Native Municipality Population Census 2001-03-01 Population Census 2011-02-01 Population Estimate 2019-12-31 ; Boženica [Bozhenitsa] At the ASCO meeting and the upcoming 24th Congress of the European Hematology Association (EHA), 13-16 June 2019, the Company will present long-term trial follow-up data showing the promising response rate, duration of response and safety profile of the Bruton’s tyrosine kinase (BTK) inhibitor These data are part of a robust development programme that includes two pivotal clinical trials for Three-year overall survival update from the PACIFIC trial.Poster Session - Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersFirst subsequent treatment after discontinuation of durvalumab in unresectable, Stage III NSCLC patients from PACIFIC.Poster Session - Lung Cancer - Non-Small Cell MetastaticBlood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in metastatic (m) NSCLC.Poster Discussion - Lung Cancer - Non-Small Cell MetastaticPatient-reported outcomes (PROs) with first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in metastatic NSCLC: results from MYSTIC.Poster Presentation - Lung Cancer - Non-Small Cell MetastaticPACIFIC-2: phase 3 study of concurrent durvalumab and platinum-based chemoradiotherapy in patients with unresectable, stage III NSCLC.Poster Presentation - Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersOlaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.Plenary Session Including the Distinguished Achievement Award and Science of Oncology Award LectureOlaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Phase III SOLO1 trial.TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.Oral Abstract Session - Genitourinary (Prostate) CancerA randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: A trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia.GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD).Oral Abstract Session - Breast Cancer -Local/Regional/AdjuvantSAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-driven (MET+), locally advanced or metastatic non-small cell lung cancer (NSCLC), following disease progression on osimertinib.Poster Session - Lung Cancer - Non-Small Cell MetastaticEarly clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial.Poster Session - Lung Cancer - Non-Small Cell MetastaticCapivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial.Acalabrutinib with obinutuzumab (Ob) in treatment-naive (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Three-year follow-up.Oral Abstract Session - Hematologic Malignancies - Lymphoma and Chronic Lymphocytic LeukemiaPhase 2 study of acalabrutinib in ibrutinib (IBR)-intolerant patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).Poster Session - Hematologic Malignancies - Lymphoma and Chronic Lymphocytic LeukemiaA phase III, multicenter, randomized, open label trial of [fam-] trastuzumab deruxtecan (DS-8201a) versus investigator’s choice in HER2-low breast cancer.In addition to the scientific presentations and press releases planned at the ASCO meeting, AstraZeneca and its partner MSD (MSD: known as Merck & Co., Inc. inside the US and Canada) will host a press briefing on Sunday 2 June, on AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly-growing portfolio of new medicines that has the potential to transform patients’ lives and the Company’s future.
Kalbarri To Shark Bay, Google Phd Salary, Cloudy In ASL, Uk Climate Model, Callus Foot Pathology Outlines, Gelson Martins Twitter, Trudeau Foundation Old Logo, Kobe Bryant Draft Class, The Paramount New Orleans, Al Bundy I Played High School Football, Precision Glass Thermometers, Adivi Sesh In Bahubali, How To Add Texture To Processing, The Alliance The Office Angela, ASL Sign For Berry, Weekend Edition Sunday Host, Beaufort Sabah Blog, Epson Printers Walmart, Highbury Square Airbnb, Abs-cbn Sports And Action Channel, Raizo One Piece Traitor, Dano Tingcungco Instagram, Next Year In Asl, Population Of Newport 2020, Vanessa Lawson Instagram, Big Brother 15 Aaryn, Richard Gene The Fishing Machine Video, Wikipedia Family Tree, Weather-oneonta, Ny 10-day, Nel Blu Dipinto Di Blu (volare Domenico Modugno), Old Gmail App, Eagle Eye Osrs, Haut Les Cœurs Larousse, Mizzou Email Format, Chicago Flood 2020, Apophis Asteroid Nasa, Servicenow Software Engineer Intern, Monty Python Ministry Of Silly Walks Youtube, Can You Eat Alpaca Meat, Amazon Strategy 2020, Oracle Oci Seattle Address, Unusual Hotels Romania, Pan American Winter Games, Vicks Rapid Read Thermometer Cvs, Ikea Bristol Click And Collect, I'm Bad Ll Cool J, Rodney Dangerfield Drugs, New Look Retail Group Limited, Mike Zimmer Vikings, Warren G Album, Lush Gift Basket, Best Stocks To Buy Under $50, Dress In Asl, Asda Double Discount Dates 2020, Can Tulips Grow In Hot Weather, Yallingup Lodge Spa Retreat Glamping, Detritivores In The Sahara Desert, Sheridan Uk Ltd, Champion Shorts Men, Angelo Pagan Jr, Hans Moleman History, Mary Brock Atlanta Dream, Rosie Wicks Page 3, Google Images Monkfish, Can Alpacas Eat Dandelions, Apophis Asteroid Nasa, The Green Flash, Tibet Earthquake 2017, Sally Jenkins Washington Post Email,